General
Preferred name
Drinabant
Synonyms
AVE-1625 ()
AVE1625 ()
AVE 1625 ()
P&D ID
PD019847
CAS
358970-97-5
Tags
available
drug candidate
Drug indication
Psychotic disorder
Alzheimer disease
Drug Status
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R[1].
PRICE
272
DESCRIPTION
Very high affinity and selective melatonin receptor agonist
(Tocris Bioactive Compound Library)
DESCRIPTION
Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
496.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
5.51
TPSA
40.62
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
6.0
QED
0.45
QED
0.45
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
CB1R
Cannabinoid Receptor
Primary Target
CB1 Receptors
MOA
Antagonist
Pathway
GPCR/G protein
Neuronal Signaling
Source data

